In our recent explorations of the life science innovation landscape in various areas of the U.S., we've looked at how different regions shape up in terms of pipeline assets, key indication areas, and the kind of investors active in each region. One metric in which we saw substantial distinctions is where assets fall in the pipeline. Not every area with an abundance of preclinical assets also has a large amount of Phase III assets that may become marketed products in the near future.